Debra birnkrant fdating

Debra birnkrant fdating

Consequently the practicalThe Ames Salmonella test and

The Ames Salmonella test and the in vitro mammalian gene mutation assays should be conducted before the first clinical trial. Before conducting the pharmacokinetic studies, appropriate analytical methods of detection and quantification of the drug substance should be established.

However, the timing of performance of each study may vary according to the requirements of the regulatory agency in each country. This test has the ability to detect the potential for producing vaginal irritation by mechanisms that may be different from those operating in the standard vaginal irritation model.

Carcinogenicity Studies Since microbicides are expected to be used chronically, their carcinogenicity potential needs to be evaluated and completed before market approval. If metabolites are formed, it is important to develop assays for their detection. In addition, it should not have a negative impact on the acidic pH of the female genital tract. Further studies should be performed to support a proposed expiry dating for the commercial product. The results from such studies can be used to supplement those from the rabbit vaginal irritation study.

Drug products are usually used in all other general toxicity studies. Formulation studies are also important, because they help in the subsequent establishment of a drug product specification tests, acceptance criteria, and analytical procedures. If the product does support microbial growth, it should be reformulated and retested using a minimum amount of an appropriate preservative.

If the product does supportFormulation studies are also important because

Finally, the value of early, well-integrated formulation research has been recognized and incorporated into the recommended development process. Therefore, it is recommended that the microbicide formulation be evaluated for compatibility with physical barriers such as condoms and diaphragms. However, if the manufacture of the vaginal microbicide product includes sterilization, sterility and endotoxin tests should be included in the final drug product specification.

Before conducting the pharmacokinetic

The scoring system usually follows that described by Eckstein et al. Sometimes, a recovery group may be incorporated into the study to determine the reversibility of an observed toxicity. In addition, the optimal microbicide vaginal formulation should have some important functional attributes, which would assist with product utility and user compliance.

Cross-resistance is not necessarily reciprocal. The release rate may be directly related to the solubility, hygroscopicity or solid-state form of the drug substance.

Drug products are

Even with this limited focus, the primary screening should include both cell-associated and cell-free virus. The model is also limited in that infection can only be accomplished with cell-associated virus. However, recent data suggest that dendritic cells may also serve as primary cell targets for infection in the course of sexual transmission. The most appropriate alternative assay for topical microbicides is probably the Tg.

The local lymph node assay in mice may be conducted in lieu of the more traditional guinea pig sensitization assay. Excipients used in the drug product should be tested for potential enhancement of infectivity. The explant model may provide a system that more closely reflects the vaginal environment. See all tables at end of this report.

The contraceptive potential of a microbicide candidate ie, toxicity to the human sperm should be studied. If irritation is evident at dose levels near those targeted for clinical studies, further development should be reconsidered. Plasma drug levels are usually monitored in these studies to determine the extent of systemic absorption after repeated drug exposure. Initial studies should assure the stability of the drug substance and the drug product for the duration of the proposed clinical trials.

Consequently, the practical value of activity data generated in this system is unknown. It is also not appropriate for comparing different semisolid formulations or for comparing similar formulations across manufacturers. Each of these areas will be discussed in this section. The route of administration should normally be the same as that used in the clinical trials ie, vaginal.

However, in vitro release testing should not be used as a surrogate test for in vivo bioavailability or bioequivalence. For example, if virus X is resistant to drug A and shows cross-resistance to drug B, virus Y, which is resistant to drug B, may still be sensitive to drug A. However, only limited data are available. However, the pigtailed macaque model may provide a useful tool for vaginal safety studies eg, assessment of irritation potential or effects on normal flora.